{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:45:37Z","timestamp":1788331537697,"version":"build-2803163510"},"reference-count":129,"publisher":"Archives of Endocrinology and Metabolism","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,21]]},"DOI":"10.20945\/2359-3997000000647","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T08:57:42Z","timestamp":1687769862000},"source":"Crossref","is-referenced-by-count":32,"title":["Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions"],"prefix":"10.20945","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-0057","authenticated-orcid":false,"given":"Leonardo de Andrade","family":"Mesquita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9884-0654","authenticated-orcid":false,"given":"Laura Fink","family":"Wayerbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7850-1644","authenticated-orcid":false,"given":"Gilberto","family":"Schwartsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5873-9498","authenticated-orcid":false,"given":"Fernando","family":"Gerchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"key":"key20230626085735_B1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.metabol.2018.10.011","article-title":"Obesity and cardiovascular disease: revisiting an old relationship","volume":"92","author":"Koliaki","year":"2019","unstructured":"1 Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98-107.","journal-title":"Metabolism"},{"issue":"10159","key":"key20230626085735_B2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Roth","year":"2018","unstructured":"2 Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736-88.","journal-title":"Lancet"},{"issue":"10258","key":"key20230626085735_B3","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Vos","year":"2020","unstructured":"3 Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22.","journal-title":"Lancet"},{"key":"key20230626085735_B4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.metabol.2018.10.013","article-title":"Burden of cancer attributable to obesity, type 2 diabetes and associated risk factors","volume":"92","author":"Lopez-Suarez","year":"2019","unstructured":"4 Lopez-Suarez A. Burden of cancer attributable to obesity, type 2 diabetes and associated risk factors. Metabolism. 2019;92:136-46.","journal-title":"Metabolism"},{"issue":"10226","key":"key20230626085735_B5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(19)32007-0","article-title":"Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study","volume":"395","author":"Dagenais","year":"2020","unstructured":"5 Dagenais GR, Leong DP, Rangarajan S, Lanas F, Lopez-Jaramillo P, Gupta R, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet. 2020;395(10226):785-94.","journal-title":"Lancet"},{"issue":"6","key":"key20230626085735_B6","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.2337\/dc15-2308","article-title":"Age-Specific Trends From 2000-2011 in All-Cause and Cause-Specific Mortality in Type 1 and Type 2 Diabetes: A Cohort Study of More Than One Million People","volume":"39","author":"Harding","year":"2016","unstructured":"6 Harding JL, Shaw JE, Peeters A, Davidson S, Magliano DJ. Age-Specific Trends From 2000-2011 in All-Cause and Cause-Specific Mortality in Type 1 and Type 2 Diabetes: A Cohort Study of More Than One Million People. Diabetes Care. 2016;39(6):1018-26.","journal-title":"Diabetes Care"},{"issue":"10138","key":"key20230626085735_B7","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(18)30314-3","article-title":"Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data","volume":"391","author":"Gregg","year":"2018","unstructured":"7 Gregg EW, Cheng YJ, Srinivasan M, Lin J, Geiss LS, Albright AL, et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet. 2018;391(10138):2430-40.","journal-title":"Lancet"},{"issue":"3","key":"key20230626085735_B8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S2213-8587(20)30431-9","article-title":"Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records","volume":"9","author":"Pearson-Stuttard","year":"2021","unstructured":"8 Pearson-Stuttard J, Bennett J, Cheng YJ, Vamos EP, Cross AJ, Ezzati M, et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021;9(3):165-73.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10026","key":"key20230626085735_B9","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","article-title":"Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants","volume":"387","author":"N NCD Risk Factor Collaboration (NCD-RisC)","year":"2016","unstructured":"9 N NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387(10026):1377-96.","journal-title":"Lancet"},{"issue":"1","key":"key20230626085735_B10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health Effects of Overweight and Obesity in 195 Countries over 25 Years","volume":"377","author":"GBD 2015 Obesity Collaborators","year":"2017","unstructured":"10 GBD 2015 Obesity Collaborators; Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377(1):13-27.","journal-title":"N Engl J Med"},{"key":"key20230626085735_B11","author":"World Obesity Federation","year":"2022","unstructured":"11 World Obesity Federation. World Obesity Atlas. 2022.","journal-title":"World Obesity Atlas"},{"key":"key20230626085735_B12","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","unstructured":"12 Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"key20230626085735_B13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","article-title":"Obesity and cancer risk: Emerging biological mechanisms and perspectives","volume":"92","author":"Avgerinos","year":"2019","unstructured":"13 Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019;92:121-35.","journal-title":"Metabolism"},{"issue":"8","key":"key20230626085735_B14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body Fatness and Cancer\u2013\u2013Viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","unstructured":"14 Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body Fatness and Cancer\u2013\u2013Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-8.","journal-title":"N Engl J Med"},{"key":"key20230626085735_B15","article-title":"Continuous Update Project Expert Report 2018","author":"World Cancer Research Fund\/American Institute for Cancer Research","unstructured":"15 World Cancer Research Fund\/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Body fatness and weight gain and the risk of cancer.","journal-title":"Body fatness and weight gain and the risk of cancer"},{"issue":"6","key":"key20230626085735_B16","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S2213-8587(18)30150-5","article-title":"Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment","volume":"6","author":"Pearson-Stuttard","year":"2018","unstructured":"16 Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6(6):e6-e15.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"key20230626085735_B17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1210\/endrev\/bnz014","article-title":"Review: Diabetes, Obesity, and Cancer-Pathophysiology and Clinical Implications","volume":"41","author":"Lega","year":"2020","unstructured":"17 Lega IC, Lipscombe LL. Review: Diabetes, Obesity, and Cancer-Pathophysiology and Clinical Implications. Endocr Rev. 2020;41(1):33-52.","journal-title":"Endocr Rev"},{"issue":"10","key":"key20230626085735_B18","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jacc.2013.06.027","article-title":"Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality","volume":"62","author":"Britton","year":"2013","unstructured":"18 Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann U, Fox CS. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol. 2013;62(10):921-5.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"key20230626085735_B19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41366-020-0519-5","article-title":"Anthropometric measures of body fat and obesity-related cancer risk: sex-specific differences in Framingham Offspring Study adults","volume":"44","author":"Chadid","year":"2020","unstructured":"19 Chadid S, Kreger BE, Singer MR, Loring Bradlee M, Moore LL. Anthropometric measures of body fat and obesity-related cancer risk: sex-specific differences in Framingham Offspring Study adults. Int J Obes (Lond). 2020;44(3):601-8.","journal-title":"Int J Obes (Lond)"},{"issue":"11","key":"key20230626085735_B20","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/bjc.2017.106","article-title":"Comparison of general obesity and measures of body fat distribution in older adults in relation to cancer risk: meta-analysis of individual participant data of seven prospective cohorts in Europe","volume":"116","author":"Freisling","year":"2017","unstructured":"20 Freisling H, Arnold M, Soerjomataram I, O'Doherty MG, Ordonez-Mena JM, Bamia C, et al. Comparison of general obesity and measures of body fat distribution in older adults in relation to cancer risk: meta-analysis of individual participant data of seven prospective cohorts in Europe. Br J Cancer. 2017;116(11):1486-97.","journal-title":"Br J Cancer"},{"issue":"1","key":"key20230626085735_B21","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13088","article-title":"Visceral obesity and incident cancer and cardiovascular disease: An integrative review of the epidemiological evidence","volume":"22","author":"Silveira","year":"2021","unstructured":"21 Silveira EA, Kliemann N, Noll M, Sarrafzadegan N, de Oliveira C. Visceral obesity and incident cancer and cardiovascular disease: An integrative review of the epidemiological evidence. Obes Rev. 2021;22(1):e13088.","journal-title":"Obes Rev"},{"issue":"1","key":"key20230626085735_B22","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1038\/s41598-019-41550-1","article-title":"Cancer risk in relation to body fat distribution, evaluated by DXA-scans, in postmenopausal women \u2013 the Prospective Epidemiological Risk Factor (PERF) study","volume":"9","author":"Staunstrup","year":"2019","unstructured":"22 Staunstrup LM, Nielsen HB, Pedersen BK, Karsdal M, Blair JPM, Christensen JF, et al. Cancer risk in relation to body fat distribution, evaluated by DXA-scans, in postmenopausal women \u2013 the Prospective Epidemiological Risk Factor (PERF) study. Sci Rep. 2019;9(1):5379.","journal-title":"Sci Rep"},{"issue":"1","key":"key20230626085735_B23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12916-020-01848-8","article-title":"Associations of six adiposity-related markers with incidence and mortality from 24 cancers-findings from the UK Biobank prospective cohort study","volume":"19","author":"Parra-Soto","year":"2021","unstructured":"23 Parra-Soto S, Cowley ES, Rezende LFM, Ferreccio C, Mathers JC, Pell JP, et al. Associations of six adiposity-related markers with incidence and mortality from 24 cancers-findings from the UK Biobank prospective cohort study. BMC Med. 2021;19(1):7.","journal-title":"BMC Med"},{"issue":"1","key":"key20230626085735_B24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1373\/clinchem.2017.277376","article-title":"Obesity and Cancer: Evidence, Impact, and Future Directions","volume":"64","author":"Colditz","year":"2018","unstructured":"24 Colditz GA, Peterson LL. Obesity and Cancer: Evidence, Impact, and Future Directions. Clin Chem. 2018;64(1):154-62.","journal-title":"Clin Chem"},{"issue":"3","key":"key20230626085735_B25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S2213-8587(20)30019-X","article-title":"Adolescent obesity and midlife cancer risk: a population-based cohort study of 2.3 million adolescents in Israel","volume":"8","author":"Furer","year":"2020","unstructured":"25 Furer A, Afek A, Sommer A, Keinan-Boker L, Derazne E, Levi Z, et al. Adolescent obesity and midlife cancer risk: a population-based cohort study of 2.3 million adolescents in Israel. Lancet Diabetes Endocrinol. 2020;8(3):216-25.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20230626085735_B26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.metabol.2018.12.001","article-title":"Childhood obesity: increased risk for cardiometabolic disease and cancer in adulthood","volume":"92","author":"Weihrauch-Bluher","year":"2019","unstructured":"26 Weihrauch-Bluher S, Schwarz P, Klusmann JH. Childhood obesity: increased risk for cardiometabolic disease and cancer in adulthood. Metabolism. 2019;92:147-52.","journal-title":"Metabolism"},{"issue":"12","key":"key20230626085735_B27","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/s41416-018-0106-x","article-title":"Midlife weight gain is a risk factor for obesity-related cancer","volume":"118","author":"Chadid","year":"2018","unstructured":"27 Chadid S, Singer MR, Kreger BE, Bradlee ML, Moore LL. Midlife weight gain is a risk factor for obesity-related cancer. Br J Cancer. 2018;118(12):1665-71.","journal-title":"Br J Cancer"},{"issue":"5","key":"key20230626085735_B28","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41416-018-0240-5","article-title":"Excess body weight, weight gain and obesity-related cancer risk in women in Norway: the Norwegian Women and Cancer study","volume":"119","author":"da Silva","year":"2018","unstructured":"28 da Silva M, Weiderpass E, Licaj I, Lissner L, Rylander C. Excess body weight, weight gain and obesity-related cancer risk in women in Norway: the Norwegian Women and Cancer study. Br J Cancer. 2018;119(5):646-56.","journal-title":"Br J Cancer"},{"issue":"5","key":"key20230626085735_B29","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ijc.31743","article-title":"Weight change since age 20 and incident risk of obesity-related cancer in Japan: a pooled analysis of the Miyagi Cohort Study and the Ohsaki Cohort Study","volume":"144","author":"Wakamatsu","year":"2019","unstructured":"29 Wakamatsu M, Sugawara Y, Zhang S, Tanji F, Tomata Y, Tsuji I. Weight change since age 20 and incident risk of obesity-related cancer in Japan: a pooled analysis of the Miyagi Cohort Study and the Ohsaki Cohort Study. Int J Cancer. 2019;144(5):967-80.","journal-title":"Int J Cancer"},{"issue":"3","key":"key20230626085735_B30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jama.2017.7092","article-title":"Associations of Weight Gain from Early to Middle Adulthood with Major Health Outcomes Later in Life","volume":"318","author":"Zheng","year":"2017","unstructured":"30 Zheng Y, Manson JE, Yuan C, Liang MH, Grodstein F, Stampfer MJ, et al. Associations of Weight Gain from Early to Middle Adulthood with Major Health Outcomes Later in Life. JAMA. 2017;318(3):255-69.","journal-title":"JAMA"},{"issue":"10","key":"key20230626085735_B31","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13049","article-title":"The association between metabolically healthy obesity and risk of cancer: A systematic review and meta-analysis of prospective cohort studies","volume":"21","author":"Lin","year":"2020","unstructured":"31 Lin CJ, Chang YC, Cheng TY, Lo K, Liu SJ, Yeh TL. The association between metabolically healthy obesity and risk of cancer: A systematic review and meta-analysis of prospective cohort studies. Obes Rev. 2020;21(10):e13049.","journal-title":"Obes Rev"},{"issue":"17","key":"key20230626085735_B32","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","unstructured":"32 Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-38.","journal-title":"N Engl J Med"},{"issue":"6","key":"key20230626085735_B33","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.clnu.2018.12.011","article-title":"Obesity survival paradox in cancer patients: Results from the Physical Frailty in older adult cancer patients (PF-EC) study","volume":"38","author":"Pamoukdjian","year":"2019","unstructured":"33 Pamoukdjian F, Aparicio T, Canoui-Poitrine F, Duchemann B, Levy V, Wind P, et al. Obesity survival paradox in cancer patients: Results from the Physical Frailty in older adult cancer patients (PF-EC) study. Clin Nutr. 2019;38(6):2806-12.","journal-title":"Clin Nutr"},{"issue":"3","key":"key20230626085735_B34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3520","article-title":"Association of Obesity with Survival Outcomes in Patients with Cancer: A Systematic Review and Meta-analysis","volume":"4","author":"Petrelli","year":"2021","unstructured":"34 Petrelli F, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, et al. Association of Obesity with Survival Outcomes in Patients with Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4(3):e213520.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"key20230626085735_B35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40519-018-0489-y","article-title":"The obesity paradox in cancer: clinical insights and perspectives","volume":"23","author":"Trestini","year":"2018","unstructured":"35 Trestini I, Carbognin L, Bonaiuto C, Tortora G, Bria E. The obesity paradox in cancer: clinical insights and perspectives. Eat Weight Disord. 2018;23(2):185-93.","journal-title":"Eat Weight Disord"},{"issue":"3","key":"key20230626085735_B36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13668-019-00280-6","article-title":"The Obesity Paradox in Cancer: Epidemiologic Insights and Perspectives","volume":"8","author":"Lee","year":"2019","unstructured":"36 Lee DH, Giovannucci EL. The Obesity Paradox in Cancer: Epidemiologic Insights and Perspectives. Curr Nutr Rep. 2019;8(3):175-81.","journal-title":"Curr Nutr Rep"},{"issue":"3","key":"key20230626085735_B37","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/cd19-0077","article-title":"Review of Associations Between Type 2 Diabetes and Cancer","volume":"38","author":"Bonagiri","year":"2020","unstructured":"37 Bonagiri PR, Shubrook JH. Review of Associations Between Type 2 Diabetes and Cancer. Clin Diabetes. 2020;38(3):256-65.","journal-title":"Clin Diabetes"},{"issue":"6","key":"key20230626085735_B38","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1158\/1055-9965.EPI-20-1245","article-title":"Type 2 Diabetes and Cancer: An Umbrella Review of Observational and Mendelian Randomization Studies","volume":"30","author":"Pearson-Stuttard","year":"2021","unstructured":"38 Pearson-Stuttard J, Papadimitriou N, Markozannes G, Cividini S, Kakourou A, Gill D, et al. Type 2 Diabetes and Cancer: An Umbrella Review of Observational and Mendelian Randomization Studies. Cancer Epidemiol Biomarkers Prev. 2021;30(6):1218-28.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"key20230626085735_B39","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.2337\/dc20-0204","article-title":"Association of Type 2 Diabetes with Cancer: A Meta-analysis With Bias Analysis for Unmeasured Confounding in 151 Cohorts Comprising 32 Million People","volume":"43","author":"Ling","year":"2020","unstructured":"39 Ling S, Brown K, Miksza JK, Howells L, Morrison A, Issa E, et al. Association of Type 2 Diabetes with Cancer: A Meta-analysis With Bias Analysis for Unmeasured Confounding in 151 Cohorts Comprising 32 Million People. Diabetes Care. 2020;43(9):2313-22.","journal-title":"Diabetes Care"},{"issue":"11","key":"key20230626085735_B40","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00125-014-3361-2","article-title":"Prediabetes and the risk of cancer: a meta-analysis","volume":"57","author":"Huang","year":"2014","unstructured":"40 Huang Y, Cai X, Qiu M, Chen P, Tang H, Hu Y, et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia. 2014;57(11):2261-9.","journal-title":"Diabetologia"},{"issue":"2","key":"key20230626085735_B41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12020-016-1216-y","article-title":"Insights into the relationships between diabetes, prediabetes, and cancer","volume":"56","author":"Scappaticcio","year":"2017","unstructured":"41 Scappaticcio L, Maiorino MI, Bellastella G, Giugliano D, Esposito K. Insights into the relationships between diabetes, prediabetes, and cancer. Endocrine. 2017;56(2):231-9.","journal-title":"Endocrine"},{"issue":"5","key":"key20230626085735_B42","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/jjco\/hyy047","article-title":"Type 1 diabetes mellitus and risk of cancer: a meta-analysis of observational studies","volume":"48","author":"Sona","year":"2018","unstructured":"42 Sona MF, Myung SK, Park K, Jargalsaikhan G. Type 1 diabetes mellitus and risk of cancer: a meta-analysis of observational studies. Jpn J Clin Oncol. 2018;48(5):426-33.","journal-title":"Jpn J Clin Oncol"},{"issue":"17","key":"key20230626085735_B43","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1002\/cncr.30095","article-title":"The temporal relationship between diabetes and cancer: A population-based study","volume":"122","author":"Lega","year":"2016","unstructured":"43 Lega IC, Wilton AS, Austin PC, Fischer HD, Johnson JA, Lipscombe LL. The temporal relationship between diabetes and cancer: A population-based study. Cancer. 2016;122(17):2731-8.","journal-title":"Cancer"},{"issue":"1","key":"key20230626085735_B44","doi-asserted-by":"crossref","first-page":"17376","DOI":"10.1038\/s41598-020-73668-y","article-title":"A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time","volume":"10","author":"Bjornsdottir","year":"2020","unstructured":"44 Bjornsdottir HH, Rawshani A, Rawshani A, Franzen S, Svensson AM, Sattar N, et al. A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time. Sci Rep. 2020;10(1):17376.","journal-title":"Sci Rep"},{"issue":"6","key":"key20230626085735_B45","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s00125-017-4229-z","article-title":"Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium","volume":"60","author":"Chen","year":"2017","unstructured":"45 Chen Y, Wu F, Saito E, Lin Y, Song M, Luu HN, et al. Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium. Diabetologia. 2017;60(6):1022-32.","journal-title":"Diabetologia"},{"issue":"1","key":"key20230626085735_B46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00125-019-04991-x","article-title":"Trends in cancer mortality among people with vs without diabetes in the USA, 1988-2015","volume":"63","author":"Harding","year":"2020","unstructured":"46 Harding JL, Andes LJ, Gregg EW, Cheng YJ, Weir HK, Bullard KM, et al. Trends in cancer mortality among people with vs without diabetes in the USA, 1988-2015. Diabetologia. 2020;63(1):75-84.","journal-title":"Diabetologia"},{"issue":"23","key":"key20230626085735_B47","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1001\/jama.2008.824","article-title":"Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis","volume":"300","author":"Barone","year":"2008","unstructured":"47 Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300(23):2754-64.","journal-title":"JAMA"},{"issue":"11","key":"key20230626085735_B48","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/1055-9965.EPI-06-0410","article-title":"A meta-analysis of diabetes mellitus and the risk of prostate cancer","volume":"15","author":"Kasper","year":"2006","unstructured":"48 Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2056-62.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"key20230626085735_B49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/pcan.2012.40","article-title":"Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies","volume":"16","author":"Bansal","year":"2013","unstructured":"49 Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16(2):151-8, S1.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"key20230626085735_B50","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ijc.28989","article-title":"Diabetes mellitus and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition","volume":"136","author":"Tsilidis","year":"2015","unstructured":"50 Tsilidis KK, Allen NE, Appleby PN, Rohrmann S, Nothlings U, Arriola L, et al. Diabetes mellitus and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2015;136(2):372-81.","journal-title":"Int J Cancer"},{"issue":"6","key":"key20230626085735_B51","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1158\/1055-9965.EPI-19-1623","article-title":"Diabetes, Glycated Hemoglobin, and Risk of Cancer in the UK Biobank Study","volume":"29","author":"Peila","year":"2020","unstructured":"51 Peila R, Rohan TE. Diabetes, Glycated Hemoglobin, and Risk of Cancer in the UK Biobank Study. Cancer Epidemiol Biomarkers Prev. 2020;29(6):1107-19.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20230626085735_B52","doi-asserted-by":"crossref","first-page":"109229","DOI":"10.1016\/j.diabres.2022.109229","article-title":"Long-Term patterns of cancer incidence among patients with and without type 2 diabetes in the United Kingdom","volume":"185","author":"Pradhan","year":"2022","unstructured":"52 Pradhan R, Yu O, Platt RW, Azoulay L. Long-Term patterns of cancer incidence among patients with and without type 2 diabetes in the United Kingdom. Diabetes Res Clin Pract. 2022;185:109229.","journal-title":"Diabetes Res Clin Pract"},{"key":"key20230626085735_B53","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.diabres.2018.04.002","article-title":"Diabetes and cancer: Pathophysiological fundamentals of a \u2018dangerous affair\u2019","volume":"143","author":"Cignarelli","year":"2018","unstructured":"53 Cignarelli A, Genchi VA, Caruso I, Natalicchio A, Perrini S, Laviola L, et al. Diabetes and cancer: Pathophysiological fundamentals of a \u2018dangerous affair\u2019. Diabetes Res Clin Pract. 2018;143:378-88.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"key20230626085735_B54","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4093\/dmj.2021.0077","article-title":"Obesity, Diabetes, and Increased Cancer Progression","volume":"45","author":"Kim","year":"2021","unstructured":"54 Kim DS, Scherer PE. Obesity, Diabetes, and Increased Cancer Progression. Diabetes Metab J. 2021;45(6):799-812.","journal-title":"Diabetes Metab J"},{"key":"key20230626085735_B55","doi-asserted-by":"crossref","first-page":"600824","DOI":"10.3389\/fonc.2020.600824","article-title":"Type 2 Diabetes, Obesity, and Cancer Share Some Common and Critical Pathways","volume":"10","author":"Rahman","year":"2020","unstructured":"55 Rahman I, Athar MT, Islam M. Type 2 Diabetes, Obesity, and Cancer Share Some Common and Critical Pathways. Front Oncol. 2020;10:600824.","journal-title":"Front Oncol"},{"key":"key20230626085735_B56","doi-asserted-by":"crossref","first-page":"615375","DOI":"10.3389\/fonc.2020.615375","article-title":"Obesity, Type 2 Diabetes, and Cancer Risk","volume":"10","author":"Scully","year":"2020","unstructured":"56 Scully T, Ettela A, LeRoith D, Gallagher EJ. Obesity, Type 2 Diabetes, and Cancer Risk. Front Oncol. 2020;10:615375.","journal-title":"Front Oncol"},{"issue":"12","key":"key20230626085735_B57","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nrc3174","article-title":"Molecular mechanisms of cancer development in obesity","volume":"11","author":"Khandekar","year":"2011","unstructured":"57 Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11(12):886-95.","journal-title":"Nat Rev Cancer"},{"issue":"35","key":"key20230626085735_B58","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2016.67.9712","article-title":"Obesity and Cancer Mechanisms: Cancer Metabolism","volume":"34","author":"Hopkins","year":"2016","unstructured":"58 Hopkins BD, Goncalves MD, Cantley LC. Obesity and Cancer Mechanisms: Cancer Metabolism. J Clin Oncol. 2016;34(35):4277-83.","journal-title":"J Clin Oncol"},{"issue":"4","key":"key20230626085735_B59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.orcp.2019.03.006","article-title":"Circulating adipokines and risk of obesity related cancers: A systematic review and meta-analysis","volume":"13","author":"Yoon","year":"2019","unstructured":"59 Yoon YS, Kwon AR, Lee YK, Oh SW. Circulating adipokines and risk of obesity related cancers: A systematic review and meta-analysis. Obes Res Clin Pract. 2019;13(4):329-39.","journal-title":"Obes Res Clin Pract"},{"issue":"3","key":"key20230626085735_B60","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4093\/dmj.2020.0250","article-title":"Hyperinsulinemia in Obesity, Inflammation, and Cancer","volume":"45","author":"Zhang","year":"2021","unstructured":"60 Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in Obesity, Inflammation, and Cancer. Diabetes Metab J. 2021;45(3):285-311.","journal-title":"Diabetes Metab J"},{"issue":"3191","key":"key20230626085735_B61","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","unstructured":"61 Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-14.","journal-title":"Science"},{"issue":"8","key":"key20230626085735_B62","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrc3967","article-title":"Adiposity and cancer risk: new mechanistic insights from epidemiology","volume":"15","author":"Renehan","year":"2015","unstructured":"62 Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15(8):484-98.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"key20230626085735_B63","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41416-020-01154-3","article-title":"Cancer prevention through weight control-where are we in 2020?","volume":"124","author":"Anderson","year":"2021","unstructured":"63 Anderson AS, Renehan AG, Saxton JM, Bell J, Cade J, Cross AJ, et al. Cancer prevention through weight control-where are we in 2020? Br J Cancer. 2021;124(6):1049-56.","journal-title":"Br J Cancer"},{"issue":"12","key":"key20230626085735_B64","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/sj.ijo.0802437","article-title":"Intentional weight loss and incidence of obesity-related cancers: the Iowa Women's Health Study","volume":"27","author":"Parker","year":"2003","unstructured":"64 Parker ED, Folsom AR. Intentional weight loss and incidence of obesity-related cancers: the Iowa Women's Health Study. Int J Obes Relat Metab Disord. 2003;27(12):1447-52.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"4","key":"key20230626085735_B65","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz054","article-title":"Intentional Weight Loss and Obesity-Related Cancer Risk","volume":"3","author":"Luo","year":"2019","unstructured":"65 Luo J, Hendryx M, Manson JE, Figueiredo JC, LeBlanc ES, Barrington W, et al. Intentional Weight Loss and Obesity-Related Cancer Risk. JNCI Cancer Spectr. 2019;3(4):pkz054.","journal-title":"JNCI Cancer Spectr"},{"issue":"10","key":"key20230626085735_B66","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1467-789X.2012.01010.x","article-title":"A systematic review of the impact of weight loss on cancer incidence and mortality","volume":"13","author":"Birks","year":"2012","unstructured":"66 Birks S, Peeters A, Backholer K, O'Brien P, Brown W. A systematic review of the impact of weight loss on cancer incidence and mortality. Obes Rev. 2012;13(10):868-91.","journal-title":"Obes Rev"},{"key":"key20230626085735_B67","article-title":"Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis","volume":"359","author":"Ma","year":"2017","unstructured":"67 Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ. 2017;359:j4849.","journal-title":"BMJ"},{"issue":"9","key":"key20230626085735_B68","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/oby.22936","article-title":"Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial","volume":"28","author":"Look Ahead Research Group","year":"2020","unstructured":"68 Look Ahead Research Group; Yeh HC, Bantle JP, Cassidy-Begay M, Blackburn G, Bray GA, et al. Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. Obesity (Silver Spring). 2020;28(9):1678-86.","journal-title":"Obesity (Silver Spring)"},{"key":"key20230626085735_B69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canep.2018.10.010","article-title":"A historical cohort study on glycemic-control and cancer-risk among patients with diabetes","volume":"57","author":"Dankner","year":"2018","unstructured":"69 Dankner R, Boker LK, Boffetta P, Balicer RD, Murad H, Berlin A, et al. A historical cohort study on glycemic-control and cancer-risk among patients with diabetes. Cancer Epidemiol. 2018;57:104-9.","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"key20230626085735_B70","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12020-020-02376-4","article-title":"Glycemic control and the incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"70","author":"Lin","year":"2020","unstructured":"70 Lin C, Cai X, Yang W, Lv F, Nie L, Ji L. Glycemic control and the incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Endocrine. 2020;70(2):232-42.","journal-title":"Endocrine"},{"key":"key20230626085735_B71","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"71 American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125-S43.","journal-title":"Diabetes Care"},{"issue":"9","key":"key20230626085735_B72","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00125-017-4372-6","article-title":"Repurposing metformin for the prevention of cancer and cancer recurrence","volume":"60","author":"Heckman-Stoddard","year":"2017","unstructured":"72 Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia. 2017;60(9):1639-47.","journal-title":"Diabetologia"},{"issue":"7503","key":"key20230626085735_B73","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","unstructured":"73 Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304-5.","journal-title":"BMJ"},{"issue":"9","key":"key20230626085735_B74","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2337\/dc08-2175","article-title":"New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes","volume":"32","author":"Libby","year":"2009","unstructured":"74 Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9):1620-5.","journal-title":"Diabetes Care"},{"issue":"9","key":"key20230626085735_B75","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","article-title":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","volume":"7","author":"Gandini","year":"2014","unstructured":"75 Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila). 2014;7(9):867-85.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"key20230626085735_B76","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pcd.2020.06.001","article-title":"Metformin and risk of cancer among patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2021","unstructured":"76 Zhang K, Bai P, Dai H, Deng Z. Metformin and risk of cancer among patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Prim Care Diabetes. 2021;15(1):52-8.","journal-title":"Prim Care Diabetes"},{"issue":"10","key":"key20230626085735_B77","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1007\/s00125-012-2653-7","article-title":"Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials","volume":"55","author":"Stevens","year":"2012","unstructured":"77 Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia. 2012;55(10):2593-603.","journal-title":"Diabetologia"},{"issue":"1","key":"key20230626085735_B78","doi-asserted-by":"crossref","first-page":"10147","DOI":"10.1038\/srep10147","article-title":"Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies","volume":"5","author":"Wu","year":"2015","unstructured":"78 Wu L, Zhu J, Prokop LJ, Murad MH. Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies. Sci Rep. 2015;5(1):10147.","journal-title":"Sci Rep"},{"issue":"12","key":"key20230626085735_B79","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2337\/dc12-0788","article-title":"Metformin and the risk of cancer: time-related biases in observational studies","volume":"35","author":"Suissa","year":"2012","unstructured":"79 Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35(12):2665-73.","journal-title":"Diabetes Care"},{"issue":"9702","key":"key20230626085735_B80","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Diabetes Prevention Program Research Group","year":"2009","unstructured":"80 Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-86.","journal-title":"Lancet"},{"issue":"13","key":"key20230626085735_B81","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2165\/00003495-200363130-00004","article-title":"Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence","volume":"63","author":"Diamant","year":"2003","unstructured":"81 Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 2003;63(13):1373-405.","journal-title":"Drugs"},{"issue":"4","key":"key20230626085735_B82","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1517\/14740338.2012.691963","article-title":"Thiazolidinedione safety","volume":"11","author":"Kung","year":"2012","unstructured":"82 Kung J, Henry RR. Thiazolidinedione safety. Expert Opin Drug Saf. 2012;11(4):565-79.","journal-title":"Expert Opin Drug Saf"},{"issue":"9493","key":"key20230626085735_B83","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","unstructured":"83 Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-89.","journal-title":"Lancet"},{"issue":"4","key":"key20230626085735_B84","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cam4.1354","article-title":"Pioglitazone and bladder cancer risk: a systematic review and meta-analysis","volume":"7","author":"Tang","year":"2018","unstructured":"84 Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y, et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. Cancer Med. 2018;7(4):1070-80.","journal-title":"Cancer Med"},{"issue":"1","key":"key20230626085735_B85","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dme.13854","article-title":"A systematic review of observational studies of the association between pioglitazone use and bladder cancer","volume":"36","author":"Ripamonti","year":"2019","unstructured":"85 Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, Suissa S. A systematic review of observational studies of the association between pioglitazone use and bladder cancer. Diabet Med. 2019;36(1):22-35.","journal-title":"Diabet Med"},{"issue":"10","key":"key20230626085735_B86","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang","year":"2017","unstructured":"86 Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017;60(10):1862-72.","journal-title":"Diabetologia"},{"issue":"12","key":"key20230626085735_B87","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1007\/s00125-017-4430-0","article-title":"Bladder cancer in the EMPA-REG OUTCOME trial","volume":"60","author":"Kohler","year":"2017","unstructured":"87 Kohler S, Lee J, George JT, Inzucchi SE, Zinman B. Bladder cancer in the EMPA-REG OUTCOME trial. Diabetologia. 2017;60(12):2534-5.","journal-title":"Diabetologia"},{"issue":"12","key":"key20230626085735_B88","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00125-017-4434-9","article-title":"SGLT2 inhibitors and cancer: why further evidence is required","volume":"60","author":"Shaikh","year":"2017","unstructured":"88 Shaikh AMY. SGLT2 inhibitors and cancer: why further evidence is required. Diabetologia. 2017;60(12):2536-7.","journal-title":"Diabetologia"},{"issue":"8","key":"key20230626085735_B89","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/dom.13745","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials","volume":"21","author":"Dicembrini","year":"2019","unstructured":"89 Dicembrini I, Nreu B, Mannucci E, Monami M. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2019;21(8):1871-7.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"key20230626085735_B90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","unstructured":"90 Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22.","journal-title":"N Engl J Med"},{"issue":"11","key":"key20230626085735_B91","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","unstructured":"91 Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20230626085735_B92","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","unstructured":"92 Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473-86.","journal-title":"Endocrinology"},{"issue":"1","key":"key20230626085735_B93","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","unstructured":"93 Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150-6.","journal-title":"Gastroenterology"},{"issue":"5","key":"key20230626085735_B94","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.2337\/db11-1109","article-title":"Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model","volume":"61","author":"Gier","year":"2012","unstructured":"94 Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes. 2012;61(5):1250-62.","journal-title":"Diabetes"},{"issue":"7","key":"key20230626085735_B95","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","volume":"62","author":"Butler","year":"2013","unstructured":"95 Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62(7):2595-604.","journal-title":"Diabetes"},{"issue":"1","key":"key20230626085735_B96","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/s41598-017-19055-6","article-title":"Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis","volume":"8","author":"Pinto","year":"2018","unstructured":"96 Pinto LC, Rados DV, Barkan SS, Leitao CB, Gross JL. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis. Sci Rep. 2018;8(1):782.","journal-title":"Sci Rep"},{"issue":"5","key":"key20230626085735_B97","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3004","article-title":"Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis","volume":"34","author":"Overbeek","year":"2018","unstructured":"97 Overbeek JA, Bakker M, van der Heijden A, van Herk-Sukel MPP, Herings RMC, Nijpels G. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2018;34(5):e3004.","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"key20230626085735_B98","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/s41598-019-38956-2","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis","volume":"9","author":"Pinto","year":"2019","unstructured":"98 Pinto LC, Falcetta MR, Rados DV, Leitao CB, Gross JL. Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis. Sci Rep. 2019;9(1):2375.","journal-title":"Sci Rep"},{"issue":"4","key":"key20230626085735_B99","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2020","unstructured":"99 Abd El Aziz M, Cahyadi O, Meier JJ, Schmidt WE, Nauck MA. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab. 2020;22(4):699-704.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"key20230626085735_B100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00592-020-01479-8","article-title":"Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials","volume":"57","author":"Dicembrini","year":"2020","unstructured":"100 Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M. Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Acta Diabetol. 2020;57(6):689-96.","journal-title":"Acta Diabetol"},{"issue":"3","key":"key20230626085735_B101","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1210\/clinem\/dgaa891","article-title":"Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis","volume":"106","author":"Piccoli","year":"2021","unstructured":"101 Piccoli GF, Mesquita LA, Stein C, Aziz M, Zoldan M, Degobi NAH, et al. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2021;106(3):912-21.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20230626085735_B102","article-title":"Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study","volume":"363","author":"Abrahami","year":"2018","unstructured":"102 Abrahami D, Douros A, Yin H, Yu OH, Faillie JL, Montastruc F, et al. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ. 2018;363:k4880.","journal-title":"BMJ"},{"issue":"5","key":"key20230626085735_B103","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.numecd.2018.02.010","article-title":"Long-acting insulin analogs and cancer","volume":"28","author":"Sciacca","year":"2018","unstructured":"103 Sciacca L, Vella V, Frittitta L, Tumminia A, Manzella L, Squatrito S, et al. Long-acting insulin analogs and cancer. Nutr Metab Cardiovasc Dis. 2018;28(5):436-43.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"key20230626085735_B104","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/j.gastro.2004.07.011","article-title":"Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients","volume":"127","author":"Yang","year":"2004","unstructured":"104 Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004;127(4):1044-50.","journal-title":"Gastroenterology"},{"issue":"9","key":"key20230626085735_B105","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00125-009-1444-2","article-title":"Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden","volume":"52","author":"Jonasson","year":"2009","unstructured":"105 Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009;52(9):1745-54.","journal-title":"Diabetologia"},{"issue":"9","key":"key20230626085735_B106","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00125-009-1418-4","article-title":"Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study","volume":"52","author":"Hemkens","year":"2009","unstructured":"106 Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52(9):1732-44.","journal-title":"Diabetologia"},{"issue":"9","key":"key20230626085735_B107","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"Currie","year":"2009","unstructured":"107 Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766-77.","journal-title":"Diabetologia"},{"issue":"9","key":"key20230626085735_B108","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00125-009-1453-1","article-title":"Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group","volume":"52","author":"Colhoun","year":"2009","unstructured":"108 Colhoun HM, Group SE. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52(9):1755-65.","journal-title":"Diabetologia"},{"key":"key20230626085735_B109","first-page":"1254","article-title":"Comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry","volume":"59","author":"Carstensen","unstructured":"109 Carstensen B. Comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes;59:1254-1260. Diabetes. 2010;59(9):e17-8; author reply e9-22.","journal-title":"Diabetes"},{"issue":"5","key":"key20230626085735_B110","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s00125-010-1675-2","article-title":"Diabetes therapy and cancer risk: causal effects and other plausible explanations","volume":"53","author":"Hernandez-Diaz","year":"2010","unstructured":"110 Hernandez-Diaz S, Adami HO. Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia. 2010;53(5):802-8.","journal-title":"Diabetologia"},{"issue":"9689","key":"key20230626085735_B111","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0140-6736(09)61307-6","article-title":"Insulin glargine and malignancy: an unwarranted alarm","volume":"374","author":"Pocock","year":"2009","unstructured":"111 Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet. 2009;374(9689):511-3.","journal-title":"Lancet"},{"issue":"6","key":"key20230626085735_B112","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.diabet.2012.08.011","article-title":"Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies","volume":"38","author":"Colmers","year":"2012","unstructured":"112 Colmers IN, Bowker SL, Tjosvold LA, Johnson JA. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab. 2012;38(6):485-506.","journal-title":"Diabetes Metab"},{"issue":"12","key":"key20230626085735_B113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051814","article-title":"Insulin glargine and cancer risk in patients with diabetes: a meta-analysis","volume":"7","author":"Tang","year":"2012","unstructured":"113 Tang X, Yang L, He Z, Liu J. Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS One. 2012;7(12):e51814.","journal-title":"PLoS One"},{"issue":"5","key":"key20230626085735_B114","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/15680266113136660067","article-title":"Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies","volume":"8","author":"Karlstad","year":"2013","unstructured":"114 Karlstad O, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, et al. Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf. 2013;8(5):333-48.","journal-title":"Curr Drug Saf"},{"issue":"3","key":"key20230626085735_B115","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2337\/dc15-1816","article-title":"Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies","volume":"39","author":"Wu","year":"2016","unstructured":"115 Wu JW, Filion KB, Azoulay L, Doll MK, Suissa S. Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies. Diabetes Care. 2016;39(3):486-94.","journal-title":"Diabetes Care"},{"issue":"7","key":"key20230626085735_B116","doi-asserted-by":"crossref","first-page":"E1170","DOI":"10.1210\/jc.2012-1162","article-title":"Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus","volume":"97","author":"Chang","year":"2012","unstructured":"116 Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(7):E1170-5.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20230626085735_B117","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","unstructured":"117 Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245-56.","journal-title":"N Engl J Med"},{"issue":"10","key":"key20230626085735_B118","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","unstructured":"118 Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067-77.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"key20230626085735_B119","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study","volume":"20","author":"O'Neil","year":"2012","unstructured":"119 O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426-36.","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"key20230626085735_B120","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1808721","article-title":"Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients","volume":"379","author":"Bohula","year":"2018","unstructured":"120 Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, et al. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med. 2018;379(12):1107-17.","journal-title":"N Engl J Med"},{"issue":"11","key":"key20230626085735_B121","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMp2003873","article-title":"Cancer Risk Associated with Lorcaserin - The FDA's Review of the CAMELLIA-TIMI 61 Trial","volume":"383","author":"Sharretts","year":"2020","unstructured":"121 Sharretts J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. Cancer Risk Associated with Lorcaserin - The FDA's Review of the CAMELLIA-TIMI 61 Trial. N Engl J Med. 2020;383(11):1000-2.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20230626085735_B122","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13170","article-title":"Is lorcaserin really associated with increased risk of cancer? A systematic review and meta-analysis","volume":"22","author":"Andrade Mesquita","year":"2021","unstructured":"122 de Andrade Mesquita L, Fagundes Piccoli G, Richter da Natividade G, Frison Spiazzi B, Colpani V, Gerchman F. Is lorcaserin really associated with increased risk of cancer? A systematic review and meta-analysis. Obes Rev. 2021;22(3):e13170.","journal-title":"Obes Rev"},{"issue":"9","key":"key20230626085735_B123","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and Risks of Bariatric Surgery in Adults: A Review","volume":"324","author":"Arterburn","year":"2020","unstructured":"123 Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and Risks of Bariatric Surgery in Adults: A Review. JAMA. 2020;324(9):879-87.","journal-title":"JAMA"},{"issue":"12","key":"key20230626085735_B124","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00464-013-3127-9","article-title":"Effect of bariatric surgery on oncologic outcomes: a systematic review and meta-analysis","volume":"27","author":"Tee","year":"2013","unstructured":"124 Tee MC, Cao Y, Warnock GL, Hu FB, Chavarro JE. Effect of bariatric surgery on oncologic outcomes: a systematic review and meta-analysis. Surg Endosc. 2013;27(12):4449-56.","journal-title":"Surg Endosc"},{"issue":"9","key":"key20230626085735_B125","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s11695-014-1276-0","article-title":"Incidence of cancer following bariatric surgery: systematic review and meta-analysis","volume":"24","author":"Casagrande","year":"2014","unstructured":"125 Casagrande DS, Rosa DD, Umpierre D, Sarmento RA, Rodrigues CG, Schaan BD. Incidence of cancer following bariatric surgery: systematic review and meta-analysis. Obes Surg. 2014;24(9):1499-509.","journal-title":"Obes Surg"},{"issue":"11","key":"key20230626085735_B126","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1007\/s11695-016-2144-x","article-title":"Effects of Bariatric Surgery on Mortality, Cardiovascular Events, and Cancer Outcomes in Obese Patients: Systematic Review and Meta-analysis","volume":"26","author":"Zhou","year":"2016","unstructured":"126 Zhou X, Yu J, Li L, Gloy VL, Nordmann A, Tiboni M, et al. Effects of Bariatric Surgery on Mortality, Cardiovascular Events, and Cancer Outcomes in Obese Patients: Systematic Review and Meta-analysis. Obes Surg. 2016;26(11):2590-601.","journal-title":"Obes Surg"},{"issue":"3","key":"key20230626085735_B127","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s11695-018-3501-8","article-title":"Cancer Risk Following Bariatric Surgery-Systematic Review and Meta-analysis of National Population-Based Cohort Studies","volume":"29","author":"Wiggins","year":"2019","unstructured":"127 Wiggins T, Antonowicz SS, Markar SR. Cancer Risk Following Bariatric Surgery-Systematic Review and Meta-analysis of National Population-Based Cohort Studies. Obes Surg. 2019;29(3):1031-9.","journal-title":"Obes Surg"},{"issue":"4","key":"key20230626085735_B128","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s11695-019-04368-4","article-title":"Effects of Bariatric Surgery on Cancer Risk: Evidence from Meta-analysis","volume":"30","author":"Zhang","year":"2020","unstructured":"128 Zhang K, Luo Y, Dai H, Deng Z. Effects of Bariatric Surgery on Cancer Risk: Evidence from Meta-analysis. Obes Surg. 2020;30(4):1265-72.","journal-title":"Obes Surg"},{"issue":"24","key":"key20230626085735_B129","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1001\/jama.2022.9009","article-title":"Association of Bariatric Surgery with Cancer Risk and Mortality in Adults with Obesity","volume":"327","author":"Aminian","year":"2022","unstructured":"129 Aminian A, Wilson R, Al-Kurd A, Tu C, Milinovich A, Kroh M, et al. Association of Bariatric Surgery with Cancer Risk and Mortality in Adults with Obesity. JAMA. 2022;327(24):2423-33.","journal-title":"JAMA"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T08:59:00Z","timestamp":1687769940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/obesity-diabetes-and-cancer-epidemiology-pathophysiology-and-potential-interventions\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":129,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,21]]}},"alternative-id":["10.20945\/2359-3997000000647"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000647","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"e000647"}}